A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2002-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the relative bioavailability of 5 mg Glyburide/500 mg
Metformin Hydrochloride Tablets by Purepac Pharmaceutical Co. with that of 5 mg/500 mg
CLUCOVANCE® Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 5
mg/500 mg tablet) in healthy adult volunteers under fasting conditions.